Galyfilcon A

Summary

Galyfilcon A (CHEMBL3545130) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Clinical trials: 6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3545130
Name	Galyfilcon A
Type	Small molecule
Max phase	3

Also known as: Galyfilcon a, GALYFILCON A

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
Not specified	6

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00241280	Not specified	COMPLETED	Study Intended to Evaluate the Safety and Effectiveness of a Johnson & Johnson Vision Care Inc, (JJVCI) Contact Lens for Use on an Extended-wear Basis for up to 7 Days (6 Nights).
NCT00762385	Not specified	COMPLETED	Clinical Comparison of Two Silicone-Hydrogel Contact Lenses
NCT01054807	Not specified	COMPLETED	Non-Dispensing Evaluation of an Investigational Galyfilcon A Soft Contact Lens
NCT01244516	Not specified	COMPLETED	Multi-Center 2-Week Clinical Evaluation of Three Silicone Hydrogel Contact Lenses
NCT01482819	Not specified	COMPLETED	Evaluation of Daytime Corneal Swelling During Wear of Galyfilcon A Lenses
NCT01706770	Not specified	COMPLETED	Evaluation of Enfilcon A Soft Contact Lens When Compared to Galyfilcon A Soft Contact Lens

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).